Nonprofit · EIN 30-0213137
BIO VENTURES FOR GLOBAL HEALTH
Tax-exempt · SEATTLE, WA 98121
Financials
| Year ended | Form | Revenue | Expenses | Net income | Total assets | Liabilities | Net assets |
|---|---|---|---|---|---|---|---|
| December 31, 2024 | 990 | $504,858 | $2,591,563 | -$2,086,705 | $5,351,162 | $298,053 | $5,053,109 |
| December 31, 2023 | 990 | $4,702,895 | $2,437,035 | $2,265,860 | $7,501,784 | $361,970 | $7,139,814 |
Financial details: 990 for the year ended December 31, 2024
Revenue
- Contributions, gifts and grants
- $504,858
- Program service revenue
- $0
- Investment income
- $0
- Other revenue
- $0
Expenses
- Grants and similar amounts paid
- $0
- Compensation of officers, directors and key employees
- $486,109
- Other salaries and wages
- $1,343,326
- Salaries, compensation and benefits (total)
- $2,141,244
- Professional fundraising fees
- $0
- Accounting fees
- $15,820
- Occupancy
- $108,730
- Travel
- $60,287
- Depreciation
- $2,596
- Program services (functional)
- $1,805,313
- Management and general (functional)
- $309,230
- Fundraising (functional)
- $477,020
Balance sheet and other
- Total assets, start of year
- $7,501,784
- Total assets, end of year
- $5,351,162
- Total liabilities, end of year
- $298,053
- Net assets, end of year
- $5,053,109
- Land, buildings and equipment
- $7,108
- Net assets without donor restrictions
- $1,800,814
- Net assets with donor restrictions
- $3,252,295
- Gross receipts
- $504,858
- Employees
- 18
- Volunteers
- 186
- Year formed
- 2003
- State of legal domicile
- DC
From the e-filed returns the IRS publishes as XML (latest three processing years; amended returns replace the original). PDF copies at the IRS.
Officers, directors and key employees
As listed on the 990 for the year ended December 31, 2024, highest compensation first.
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| Jennifer Dent | President & CEO Trustee or director, Officer | 40 | $433,705 | $52,404 |
| Katy Graef | Vice President Programs | 40 | $190,233 | $17,993 |
| Cathyryne Manner | Vice President | 40 | $170,208 | $18,607 |
| Jim Geraghty | Chair Trustee or director, Officer | 2 | $0 | $0 |
| Rachel King | Director Trustee or director | 1 | $0 | $0 |
| Ruth Atherton | Director Trustee or director | 1 | $0 | $0 |
| Belinda Termeer | Director Trustee or director | 1 | $0 | $0 |
| Dr Julie Gralow | Director Trustee or director | 1 | $0 | $0 |
| Seringe Magueye Gueye | Director Trustee or director | 1 | $0 | $0 |
| J Leighton Read MD | Director Trustee or director | 1 | $0 | $0 |
| John Nevergole | Director Trustee or director | 2 | $0 | $0 |
990 for the year ended December 31, 2023: 11 people
| Name | Title | Hours / week | Compensation | Other / benefits |
|---|---|---|---|---|
| JENNIFER DENT | PRESIDENT & CEO Trustee or director, Officer | 40 | $405,513 | $49,381 |
| KATY GRAEF | VICE PRESIDENT PROGRAMS Key employee | 40 | $177,400 | $17,367 |
| CATHYRYNE MANNER | VICE PRESIDENT Highest-paid employee | 40 | $160,825 | $18,377 |
| JAMES GREENWOOD | CHAIR Trustee or director, Officer | 1 | $0 | $0 |
| RUTH ATHERTON | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JOSEPH DAMOND | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JIM GERAGHTY | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JULIE GRALOW | DIRECTOR Trustee or director | 1 | $0 | $0 |
| SERIGNE MAGUEYE GUEYE | DIRECTOR Trustee or director | 1 | $0 | $0 |
| J LEIGHTON READ | DIRECTOR Trustee or director | 1 | $0 | $0 |
| JOHN NEVERGOLE | DIRECTOR Trustee or director | 1 | $0 | $0 |
Address and contacts
- Address (IRS master file)
- 2101 4TH AVE STE 1950, SEATTLE, WA 98121-2312
- In care of
- % JENNIFER DENT
- Principal officer (990 for 2024)
- Jennifer Dent, 2101 Fourth Ave 1950, Seattle, WA 98121
- Signed the 990
- Jennifer Dent, President & CEO
- Phone
- (206) 880-7778
- Website
- www.bvgh.org
- Return prepared by
- JACOBSON LAWRENCE & ASSOCIATES PLLC
Mission
BVGH drives sustainable, market-informed solutions to improve access to quality healthcare in low- and middle-income countries. BVGH builds cross-sector partnerships that align industry, government, and local health-system priorities to expand access to cancer care, infectious disease technologies, and essential medicines. BVGHs flagship programs focus on strengthening cancer and infectious disease ecosystems through coordinated national strategies, capacity building, and responsible product introduction. Key activities include the African Access Initiative (AAI), which supports countries in developing cancer control plans, expanding diagnostics and treatment capacity, and improving affordability and availability of oncology products. BVGH also brokers collaborations between companies and African research institutions to advance R&D, clinical trials, workforce training, and technology transfer. These activities collectively enhance health-system readiness, accelerate access to lifesavi
Program accomplishments
- African Access Initiative (AAI): A PPP that targets the cancer crisis in Africa. Through AAI, BVGH is strengthening healthcare systems, building oncology capacity and skills, forging research and development partnerships led by African healthcare professionals, building and promoting clinical trial readiness, and creating community awareness and promoting health education. AAI has trained more than 18,000 oncology healthcare professionals, delivered access to multiple cancer medicines, and forged countless partnerships.Expenses $1,631,966
- BVGH Other Programs: BVGH develops and manages programs that advance LMIC government objectives as they relate to: public-private partnership development; strategic and implementation planning development; program implementation and management; and international partner program management (across research, health systems strengthening, workforce development, and climate and agriculture as they intersect with health). BVGH develops market assessment and entry reports for the private sector to inform short and long-term investments and decision making. Market reports include: economic and country stability and risk assessment; country SWOT analysis; market and growth potential; regulatory and payor systems analysis; innovative financing opportunities; stakeholder mapping; and more. Other programs include: laboratory and medtech systems placement, delivery, and training.Expenses $87,204
- BVGH Infectious Disease Programs (Global Innovation Alliance (GIA) and Global Innovation Alliance Network of Trial Sites (GIANTS)): BVGH catalyzes and manages global cross-organization, cross-sector collaborations to advance research and development (R&D) targeting infectious diseases with high burdens in LMICs. Through the Global Innovation Alliance (GIA), BVGH: 1.) builds and manages R&D collaborations between LMIC scientists and global partners; 2.) assesses, promotes, and fosters clinical trial capacity and inclusion in LMICs; 3.) elevates scientific expertise in LMICs through tailored capacity building programs; and 4.) evaluates and communicates program outcomes and impacts to broad and targeted global audiences. The programs strengthen laboratory capacity, support technology transfer, and advance co-developed R&D initiatives for vaccines, therapeutics, and diagnostics. By integrating country-level health system knowledge with real-world implementation data, BVGH helps partners accelerate innovation and prepare for feasible adoption pathways. This work contributes to more resilient infectious disease response systems and informed policy decision-making.Expenses $86,143
What it must file and when
IRS records say it files Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N. Its accounting year ends in December, so each return is due on the 15th day of the 5th month after that.
| Tax year | Year ended | Due | IRS public records |
|---|---|---|---|
| 2025 | December 31, 2025 | May 15, 2026 | Not on file |
| 2024 | December 31, 2024 | May 15, 2025 | 990 on file |
| 2023 | December 31, 2023 | May 15, 2024 | 990 on file |
IRS record
- EIN
- 30-0213137
- Tax-exempt status
- 501(c)(3): Charitable, religious, educational or scientific organization
- Foundation status
- Publicly supported organization (170(b)(1)(A)(vi))
- Donations deductible (Pub 78)
- Public charity, 50% deduction limit
- Exempt since
- 2003
- Accounting year ends
- December
- Files
- Form 990 or 990-EZ
- Category (NTEE)
- Health care (E120)
- Assets (IRS master file)
- $5,351,162
- Income (IRS master file)
- $504,858
Filing history
| Form | Year ended | Revenue | Expenses | Assets | Return |
|---|---|---|---|---|---|
| 990 | December 2024 | $504,858 | $2,591,563 | $5,351,162 | XML |
| 990 | December 2023 | $4,702,895 | $2,437,035 | $7,501,784 | XML |
| 990 | December 2022 | $1,971,687 | $2,227,074 | $5,354,552 | IRS |
| 990 | December 2021 | – | – | – | IRS |
| 990 | December 2020 | – | – | – | IRS |
| 990 | December 2019 | – | – | – | IRS |
990-N: the IRS bulk file holds only the latest e-Postcard per organization; earlier years come from archived copies of that file since 2020 and can have gaps (the IRS e-Postcard search lists every one). 990, 990-EZ, 990-PF, 990-T: every e-filed return in the IRS e-file index since 2019; XML for the latest three processing years, amounts from the IRS Statistics of Income extracts before that. PDF copies and determination letters at the IRS (search EIN 30-0213137).
Questions about BIO VENTURES FOR GLOBAL HEALTH
- What is the EIN of BIO VENTURES FOR GLOBAL HEALTH?
- The employer identification number (EIN) of BIO VENTURES FOR GLOBAL HEALTH is 30-0213137.
- Is BIO VENTURES FOR GLOBAL HEALTH tax-exempt?
- Yes. The IRS lists it as tax-exempt under section 501(c)(3) since 2003.
- Are donations to BIO VENTURES FOR GLOBAL HEALTH tax-deductible?
- Yes. It is listed in IRS Publication 78 (Public charity, 50% deduction limit).
- Which annual return does BIO VENTURES FOR GLOBAL HEALTH file?
- Form 990 or 990-EZ. Based on its last return; a smaller organization may file the 990-N.
- When is the next return of BIO VENTURES FOR GLOBAL HEALTH due?
- The return for tax year 2025 (the year ending December 31, 2025) is due May 15, 2026. Form 8868 extends it by six months; the 990-N cannot be extended.
- When did BIO VENTURES FOR GLOBAL HEALTH last file with the IRS?
- The latest return in the IRS public files is the 990 for the year ended December 2024.
- Who is the principal officer of BIO VENTURES FOR GLOBAL HEALTH?
- The 990 for the year ended December 31, 2024 names Jennifer Dent.
- Who are the officers and directors of BIO VENTURES FOR GLOBAL HEALTH?
- The 990 for the year ended December 31, 2024 lists 11 people; 3 received compensation from the organization, the highest $433,705 (Jennifer Dent, President & CEO).
- How much revenue does BIO VENTURES FOR GLOBAL HEALTH have?
- On its 990 for the year ended December 31, 2024 it reported revenue of $504,858, expenses of $2,591,563 and total assets of $5,351,162 at year end.
Other nonprofits in SEATTLE
- PROVIDENCE HEALTH & SERVICES OREGON EIN 51-0216587 · last filed 990 for 2024
- SEATTLE CHILDRENS HOSPITAL EIN 91-0564748 · last filed 990 for 2025
- FRED HUTCHINSON CANCER CENTER EIN 91-1935159 · last filed 990 for 2025
- PROVIDENCE HEALTH SYSTEM-SOUTHERN CALIFORNIA EIN 51-0216589 · last filed 990 for 2024
- DELTA DENTAL OF WASHINGTON EIN 91-0621480 · last filed 990 for 2024
- CHP OF WASHINGTON EIN 91-1729710 · last filed 990 for 2024
- VIRGINIA MASON MEDICAL CENTER EIN 91-0565539 · last filed 990 for 2025
- SEA MAR COMMUNITY HEALTH CENTERS EIN 91-1020139 · last filed 990 for 2025